NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

Various factors seem to have contributed to 23andMe’s decline. Its kits are a one-time product, so there is little prospect ...

Pharmaceutical companies and precision medicine companies could also use the data to develop new drugs. It wouldn’t be the ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...